Kyowa Kirin (4151.T)

Executive Summary

Kyowa Kirin is a global specialty pharmaceutical company headquartered in Tokyo, Japan, with a strong focus on innovative antibody therapeutics, recombinant proteins, and gene therapies. The company's proprietary POTELLIGENT technology platform enhances antibody-dependent cellular cytotoxicity, underpinning its leadership in antibody-based treatments. Kyowa Kirin has built a diversified portfolio across bone and mineral diseases, hematologic malignancies, and rare diseases, with approved products including burosumab (Crysvita) for X-linked hypophosphatemia and mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma. With over 72% of revenue generated overseas and a presence in more than 50 markets, the company is well-positioned for global growth. Its pipeline includes several mid-to-late stage programs, most notably KHK4951, a bispecific antibody targeting VEGF and Ang-2 for neovascular age-related macular degeneration (nAMD), currently in Phase 2 trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for KHK4951 + aflibercept in nAMD60% success